Another device, called a Hypoglycemia-Hyperglycemia Minimizer,
which was developed in a partnership with the Juvenile Diabetes
Research Foundation and the insulin-pump maker Animas, was able
to automatically predict increases and decreases in blood sugar
levels. It also was able to change insulin delivery accordingly
in a study that included 13 people between 24 and 57 years old
with type 1 diabetes. "The successful completion of this study
using the [Hypoglycemia-Hyperglycemia Minimizer] system in a
human clinical trial is a significant step forward in the
development of an advanced first-generation artificial
pancreas," Dr. Henry Anhalt, chief medical officer for Animas,
said in a statement. Kowalski is optimistic about the future
development of an artificial pancreas. "This gives me a lot of
hope that we're really starting to roll to what could be full-
blown product development," he said. Kowalski said he believes
the artificial pancreas likely will be approved in steps. "I
don't think it will be one produ